# Table of Contents

**VOLUME 1**

About the Editors ................................................................. v
About the Contributors ........................................................ vii
Introduction to Second Edition .......................................... xxxv
Table of Chapters ................................................................. xxxix

## PART I

**TRENDS IN PRODUCT CLAIMS AND DEFENSES**

### Chapter 1  What Product Liability Might Look Like in the Twenty-First Century

*James M. Beck*

§ 1:1  Introduction ................................................................. 1-1
§ 1:2  What Is a Product? ...................................................... 1-2
§ 1:3  Who Is a Manufacturer/Supplier? .............................. 1-7
§ 1:4  What Is a Defect? ..................................................... 1-10
§ 1:5  What Should Be the Standard of Liability? .................. 1-11
§ 1:6  Causation, Genetics and Genomics ............................ 1-14
§ 1:7  Injury ................................................................. 1-15
§ 1:8  Procedural Issues ..................................................... 1-16

### Chapter 2  Recent Trends in Product Claims and Product Defenses

*Lori B. Leskin & Angela R. Vicari*

§ 2:1  Overview ................................................................. 2-2
§ 2:2  Multidistrict Litigation .............................................. 2-3
  § 2:2.1  Increased Diversity in MDLs ............................. 2-3
  § 2:2.2  Consolidation ..................................................... 2-5
Chapter 3  Game-Changers: Defending Products Cases with Child Plaintiffs

Sandra Giannone Ezell & Diana M. Miller

§ 3:1  Overview ................................................................. 3-2
§ 3:2  Legal Strategies for Avoiding the “Blame Game” ........ 3-2
  § 3:2.1  Generally .......................................................... 3-2
  § 3:2.2  Contributory, Comparative, and Imputed Negligence ........................................... 3-3
| § 3:2.3 | Product Misuse and Alteration | 3-5 |
| § 3:2.4 | Parents As “Learned Intermediaries” | 3-9 |
| [A] | Learned Intermediary Doctrine | 3-9 |
| [B] | Last Clear Chance Doctrine | 3-10 |
| § 3:2.5 | State-of-the-Art/Industry Standard Defense | 3-11 |
| § 3:3 | Discovery | 3-12 |
| § 3:3.1 | Generally | 3-12 |
| § 3:3.2 | Get to Know the Parents and Siblings | 3-12 |
| § 3:3.3 | Deposing Children | 3-13 |
| § 3:4 | Sympathy at Trial: Acknowledge It | 3-15 |
| § 3:4.1 | Generally | 3-15 |
| § 3:4.2 | Voir Dire | 3-15 |
| § 3:4.3 | Trial Techniques for Cross-Examining Grieving Parents and the Injured Child | 3-16 |
| § 3:4.4 | Damages: Removing Sympathy from the Equation | 3-16 |
| [A] | Generally | 3-16 |
| [B] | Annuity Evidence | 3-17 |
| [C] | Mathematical Evidence | 3-18 |
| § 3:5 | Conclusion | 3-19 |

### Chapter 4 Preemption Defenses

*Joseph G. Petrosinelli, Ana C. Reyes & Amy Mason Saharia*

| § 4:1 | Overview | 4-2 |
| § 4:2 | Initial Considerations in Responding to Litigation | 4-3 |
| § 4:2.1 | Removal from State Court to Federal Court | 4-3 |
| § 4:2.2 | Failure to State a Claim | 4-4 |
| § 4:3 | Standard of Review; Presumptions; Rules of Interpretation; and Agency Deference | 4-4 |
| § 4:3.1 | Standard of Review | 4-4 |
| § 4:3.2 | Presumptions and Rules of Interpretation | 4-5 |
| § 4:3.3 | Agency Deference | 4-6 |
| § 4:4 | Types of Preemption | 4-7 |
| § 4:4.1 | Express Preemption and Savings Clauses | 4-7 |
| § 4:4.2 | Implied Preemption | 4-8 |
| § 4:4.3 | Impossibility Preemption | 4-9 |
| § 4:4.4 | Obstacle Preemption | 4-9 |
| § 4:4.5 | Field Preemption | 4-9 |
| § 4:4.6 | Administrative Preemption | 4-10 |
| § 4:5 | Preemption Involving Pharmaceutical Failure-to-Warn Claims | 4-12 |
§ 4:6  “Innovator Liability” in Pharmaceutical Failure-to-Warn Cases ................................................. 4-15
§ 4:7 Preemption Involving Medical Devices ................................................................. 4-16
§ 4:8 Preemption in Aviation .......................................................................................... 4-19
§ 4:9 Preemption Involving Vessels .............................................................................. 4-21
§ 4:10 Preemption Involving Motor Vehicles ................................................................. 4-22
§ 4:11 Preemption Involving Trains ............................................................................... 4-24
§ 4:12 Preemption in Other Areas: Cigarettes and Pesticides ........................................ 4-25
  § 4:12.1 Cigarettes ........................................................................................................ 4-25
  § 4:12.2 Pesticides ......................................................................................................... 4-26
§ 4:13 Conclusion ............................................................................................................ 4-26

Chapter 5  Defending Class Action Lawsuits

Mark Herrmann, Pearson N. Bownas & Katherine Garceau Sobiech

§ 5:1 Overview .................................................................................................................. 5-2
§ 5:2 Class Action Basics ................................................................................................. 5-5
  § 5:2.1 Generally ........................................................................................................... 5-5
  § 5:2.2 “Threshold” Requirements for Class Certification ........................................... 5-6
      [A] Ascertainable Class .............................................................................................. 5-6
      [B] Representative’s Membership in the Proposed Class ........................................ 5-10
      [C] Claim That Is Not Moot ...................................................................................... 5-11
  § 5:2.3 Rule 23(a) .......................................................................................................... 5-13
      [A] Generally ............................................................................................................. 5-13
      [B] Numerosity .......................................................................................................... 5-14
      [C] Commonality ...................................................................................................... 5-14
      [D] Typicality ............................................................................................................. 5-14
      [E] Adequacy .............................................................................................................. 5-15
  § 5:2.4 Rule 23(b) .......................................................................................................... 5-16
  § 5:2.5 A Subclass Must Individually Satisfy Rule 23 ................................................. 5-19
  § 5:2.6 Shady Grove Orthopedic Associates v. Allstate Insurance Co. and the Relationship Between Rule 23 and State Rules Regarding Class Certification ................................................................. 5-20
§ 5:3 Federal Subject Matter Jurisdiction Over Product Liability Class Actions ........... 5-22
  § 5:3.1 Generally ......................................................................................................... 5-22
  § 5:3.2 Class Action Fairness Act’s Jurisdictional, Removal, and Appeal Provisions .... 5-23
      [A] Expanded Diversity Jurisdiction ......................................................................... 5-23

xlvi
# Table of Contents

- [B] Exceptions ................................................................. 5-24
- [C] Liberalized Removal and Appeal Provisions .......... 5-25
- § 5:3.3 Other Sources of Diversity Jurisdiction Over Class Actions ......................................................... 5-26
- § 5:3.4 *Bristol-Myers Squibb* and Personal Jurisdiction .... 5-26
- § 5:4 Moving to Dismiss the Named Plaintiff’s Individual Claims .............................................................. 5-29
- § 5:5 Moving to Dismiss the Class Allegations .......... 5-30
- § 5:6 Precertification Discovery ........................................ 5-31
- § 5:6.1 Generally .............................................................. 5-31
- § 5:6.2 Differences Between Named Plaintiff’s and Class Members’ Claims ..................................................... 5-32
- § 5:6.3 Bifurcation of Discovery ........................................ 5-33
- § 5:6.4 Scheduling ............................................................ 5-34
- § 5:7 Communicating with Class Members .................... 5-34
- § 5:8 Moving for Summary Judgment on the Named Plaintiff’s Claims .......................................................... 5-35
- § 5:9 Prevailing on the Class Certification Decision .......... 5-36
- § 5:9.1 Generally .............................................................. 5-36
- § 5:9.2 “Triability” Arguments Against Class Certification ................................................................. 5-37
- [A] Generally .............................................................. 5-37
- [B] Individual Issues Secondary to Predominating Class Issues ..................................................... 5-40
- [C] Rule 23(c)(4)(A) Issue Certification ......................... 5-41
- [D] Choice-of-Law Issues .............................................. 5-42
- [E] *Eisen v. Carlisle & Jacquelin* .................................... 5-44
- § 5:9.3 Due Process Arguments Against Class Certification ................................................................. 5-46
- § 5:9.4 Other Arguments Against Certification .......... 5-49
- [A] Immaturity .............................................................. 5-49
- [B] Improper Expert Testimony Supporting Certification ................................................................. 5-49
- § 5:10 Pretrial Post-Certification Relief: Decertification and Appeal .......................................................... 5-52
- § 5:10.1 Generally .............................................................. 5-52
- § 5:10.2 Decertification ..................................................... 5-52
- § 5:10.3 Appeal ............................................................... 5-53
- § 5:11 Notice and Opt-Out .............................................. 5-55
- § 5:12 Trying a Product Liability Class Action ............ 5-57
Chapter 6  Litigation in Foreign Countries Against U.S. Companies

Joseph G. Petrosinelli & Ana C. Reyes

§ 6:1  Overview .......................................................................................... 6-1
§ 6:2  Initial Considerations in Responding to Foreign Litigation …………... 6-2
  § 6:2.1 Retaining Foreign Counsel .......................................................... 6-2
  § 6:2.2 International Privilege Considerations ....................................... 6-3
  § 6:2.3 Venue Challenges ..................................................................... 6-4
  § 6:2.4 Pretrial Asset Seizures ............................................................... 6-4
  § 6:2.5 Obtaining Foreign Evidence .................................................... 6-5
§ 6:3  U.S. Implications of Foreign Litigation ............................................ 6-6
  § 6:3.1 Parallel U.S. Litigation ............................................................... 6-6
  § 6:3.2 Settlement of U.S. Litigation ..................................................... 6-8
  § 6:3.3 U.S. Governmental Inquiries/Actions ......................................... 6-9
  § 6:3.4 Enforceability of Adverse Foreign Judgments ......................... 6-11
  § 6:3.5 Implications of Foreign Criminal Cases .................................... 6-16
§ 6:4  Conclusion ...................................................................................... 6-17

Chapter 7  Emerging Issues in Pharmaceutical Litigation

Allen P. Waxman, Loren H. Brown & Brooke Kim

§ 7:1  Overview .......................................................................................... 7-2
§ 7:2  Individual Claims and Coordinated Actions ................................... 7-3
  § 7:2.1 Locating the Mass Action: Jurisdictional Disputes ...................... 7-3
    [A] The Rise of the MDL .................................................................... 7-3
    [B] Preservice Removal ................................................................... 7-5
    [C] Post-BMS State Court Litigation ................................................ 7-7
  § 7:2.2 The Eroding Learned Intermediary Doctrine? ............................ 7-11
  § 7:2.3 Innovator Liability: Liability Without Product Identification ......... 7-13
  § 7:2.4 Litigation Funding .................................................................... 7-16
  § 7:2.5 Mass Torts in the Social Media Era .......................................... 7-18
§ 7:3  Promotion Inconsistent with or Beyond Product Labels ................. 7-19
  § 7:3.1 Generally ................................................................................. 7-20
  § 7:3.2 Safe Harbor Provisions of State Consumer Fraud Statutes .......... 7-20
  § 7:3.3 Class Certification in Consumer Fraud Class Actions ................... 7-22
§ 7:4  Government Investigations and Litigation ..................................... 7-24
  § 7:4.1 The Anti-Kickback Statute and False Claims Act ..................... 7-25
Table of Contents

§ 7:4.2 Enforcement Related to Opioid Products................. 7-27
§ 7:4.3 Enforcement Related to Patient Assistance
  Programs and Donations to Copay Charities ....... 7-29
§ 7:4.4 Enforcement Related to Rising Drug Cost............ 7-31
§ 7:4.5 DOJ Policy Shift............................................... 7-32
§ 7:5 Trends in Securities Claims Against Healthcare
  Companies .......................................................... 7-33
  § 7:5.1 Government Regulation of Securities Issued by
  Pharmaceutical and Biotechnology Companies..... 7-34
  § 7:5.2 Healthcare Companies Are Increasingly Facing
  Private Securities Litigation Claims............... 7-35
  § 7:5.3 The Pharmaceutical and Biotechnology
  Industry Is Susceptible to Private Litigation
  Due to an Ambiguous Disclosure Standard ....... 7-36
§ 7:6 Conclusion ........................................................ 7-40

Chapter 8 Recent Developments in Asbestos, Talc, Silica,
Tobacco, and E-Cigarette/Vaping Litigation in
the U.S. and Canada

George Gigounas, Arthur Hoffmann, David Jaroslaw,
Amy Pressman, Nancy Shane Rappaport, Wendy
Michael, Christopher Gismondi, Stephen H. Barrett,
Micah Chavin, Adam A. DeSipio, Ryan McNamara,
Sean Newland, Becky Rock, Greg Sperla &
Michael Lisanti

§ 8:1 Asbestos Litigation: United States ......................... 8-3
  § 8:1.1 The “Bare-Metal Defense” and Whether a
  Manufacturer Can Be Liable for Injuries
  Caused by Products It Did Not Make, Sell,
  or Distribute ...................................................... 8-3
  § 8:1.2 Personal Jurisdiction ........................................ 8-5
    [A] Motions to Dismiss ....................................... 8-6
    [B] Consent by Registration .................................. 8-7
    [C] Cases Spread Across More Jurisdictions .......... 8-9
    [D] Fewer Defendants Listed and/or Remaining
        after Motion to Dismiss ................................ 8-9
  § 8:1.3 Causation Rulings .......................................... 8-9
    [A] Every Exposure/Breath Causes Injury .............. 8-9
    [B] DNA............................................................. 8-13
  § 8:1.4 Workers’ Compensation Statutes Are Changing .... 8-14
  § 8:1.5 Federal Officer Removal ................................. 8-15
    [B] Logistics of Removal ..................................... 8-22

§ 8:2 Asbestos Litigation: Canada ........................................ 8-22
§ 8:2.1 Overview ............................................................... 8-22
§ 8:2.2 Federal Regulation .................................................... 8-23
§ 8:2.3 Partial Ban of Asbestos ............................................. 8-24
§ 8:2.4 Provincial Regulation ............................................... 8-25
§ 8:2.5 Canadian Asbestos-Related Litigation ....................... 8-27
[A] Product Liability Lawsuits ........................................... 8-27
[B] Class Action Lawsuits .................................................. 8-29
§ 8:2.6 Future Developments in Canadian Asbestos Litigation .... 8-31
§ 8:3 Talc Litigation: United States ...................................... 8-32
§ 8:3.1 Asbestos Contamination Cases ............................... 8-32
[A] Background ............................................................. 8-32
[A][1] Industrial and Cosmetic Talc Cases ......................... 8-32
[A][2] Asbestos Not an Intended Ingredient ......................... 8-32
[B] Verdict Trends ........................................................... 8-33
§ 8:3.2 Ovarian Cancer Caused by Talc ................................ 8-33
[A] Background ............................................................. 8-33
[B] Verdicts ................................................................. 8-34
[C] Scientific Evidence ...................................................... 8-35
[D] MDL and MCL ............................................................ 8-37
§ 8:4 Talc Litigation: Canada .............................................. 8-37
§ 8:4.1 Introduction ............................................................ 8-37
[A] Legislative Context ..................................................... 8-37
[B] New Developments .................................................... 8-39
[C] Litigation History ........................................................ 8-39
[C][1] Administrative Tribunals ......................................... 8-39
[C][2] The Kramar Class Action ........................................ 8-40
[C][3] Pending Litigation .................................................... 8-41
§ 8:4.2 Differences from the United States ......................... 8-42
[A] Legislative Context ..................................................... 8-42
[B] Litigation Context ....................................................... 8-43
§ 8:4.3 Anticipated Developments in Canada ...................... 8-43
§ 8:5 Silica Litigation: United States and Canada ............... 8-43
§ 8:5.1 Overview .............................................................. 8-43
§ 8:5.2 History of Litigation ............................................... 8-44
[A] U.S. Litigation ............................................................ 8-44
[B] Canadian Litigation .................................................... 8-45
[C] Future Developments in Canada .................................. 8-46
§ 8:6 Traditional Tobacco Litigation: United States .......... 8-46
§ 8:6.1 The “Engle Progeny” Actions ................................. 8-46
§ 8:6.2 Two Engle Progeny Cases Are Before the Florida Supreme Court ........................................ 8-47
Table of Contents

§ 8:6.3 Federal Appellate Activity and Engle Progeny Actions .................................................. 8-48
§ 8:6.4 Traditional Tobacco Litigation Continues ................................................................. 8-49
§ 8:6.5 Synergy Theory .............................................................................................................. 8-50
§ 8:7 Traditional Tobacco Litigation: Canada ............................................................................ 8-50
§ 8:7.1 Overview ......................................................................................................................... 8-50
§ 8:7.2 Health Care Cost Recovery Statutes ............................................................................... 8-50
§ 8:7.3 History of Litigation ........................................................................................................ 8-52
§ 8:7.4 Recent Developments in Case Law ................................................................................. 8-53
[A] Imperial Tobacco Canada Ltd. v. Quebec Council on Tobacco & Health ................. 8-53
[B] Differences from the United States ...................................................................................... 8-54
§ 8:8 Vape and E-Cigarette Litigation: United States ............................................................... 8-54
§ 8:8.1 The FDA Deeming Regulations ...................................................................................... 8-54
§ 8:8.2 Vaping Litigation ............................................................................................................. 8-57
§ 8:8.3 State Attorneys General Actions ..................................................................................... 8-59
§ 8:8.4 Vape and Respiratory Illness Litigation ........................................................................ 8-59
§ 8:8.5 Environmental Exposure Claims Involving Vape Products and/or E-Cigarettes ........ 8-60
§ 8:9 Vape and E-Cigarette Litigation: Canada .......................................................................... 8-60
§ 8:9.1 Overview ......................................................................................................................... 8-60
§ 8:9.2 Legislative Context ......................................................................................................... 8-62
§ 8:9.3 Litigation and Recent Developments in Case Law ......................................................... 8-64

Chapter 9 Emerging Issues in Medical Device Litigation


§ 9:1 Possible Exceptions to the Preemption of Claims Involving FDA Pre-Market-Approved Medical Devices ........................................................................................................ 9-2
§ 9:1.1 Express and Implied Preemption Principles Generally .................................................. 9-2
§ 9:1.2 Arguments for Exceptions to Preemption ....................................................................... 9-6
[A] Claims for Off-Label Use or Promotion ............................................................................. 9-6
[A][1] Express Preemption ........................................................................................................ 9-7
[A][2] Implied Preemption ........................................................................................................ 9-10
[A][3] Non-Preemption Hurdles for Off-Label Promotion Cases .............................................. 9-13
[B] Claims for Failure to Make Changes in FDA-Approved Labeling .................................. 9-15
[C] Manufacturing Defect Claims ............................................................................................. 9-18
[D] Express Warranty Claims .................................................................................................. 9-23

§ 9:2 Claims Arising from the Presence in the Operating Room of a Medical Device Manufacturer’s Sales Representative ......................................................... 9-27
§ 9:2.1 Generally ................................................................. 9-27
§ 9:2.2 Invasion of Privacy .................................................. 9-28
§ 9:2.3 Battery .................................................................... 9-30
§ 9:2.4 Negligent Advice or Lack of Advice During Procedure .............................................................................. 9-32
§ 9:2.5 Failure to Train in Use of Device .................................... 9-40
§ 9:2.6 Unauthorized Practice of Medicine .............................. 9-41
§ 9:2.7 Promotion of Off-Label Use by Not Preventing It During Procedure ................................................................. 9-43
§ 9:2.8 Recommended Practices for Manufacturer’s Representatives .................................................................................. 9-45
§ 9:3 Admissibility of 510(k) Clearance Evidence .................. 9-46
§ 9:3.1 Pre-Market Approval and 510(k) Clearance Generally ................................................................................................. 9-46
§ 9:3.2 Admissibility of 510(k) Clearance Evidence Under Traditional Product Liability Rules .................................................. 9-48
§ 9:3.3 Arguments Against Admissibility of 510(k) Clearance Evidence ...................................................................................... 9-49
§ 9:3.4 Arguments in Favor of Admissibility of 510(k) Clearance Evidence ...................................................................................... 9-52

Chapter 10 Emerging Issues in Automotive Product Liability Litigation Eric P. Conn, Howard A. Fried, Thomas N. Lurie & Nina A. Rosenbach

§ 10:1 Levels of Autonomy ..................................................... 10-2
§ 10:2 Safety Standards and Regulations for Fully Autonomous Vehicles ....................................................................................... 10-4
§ 10:3 Liability for Malfunctions and Breaches in Autonomous Vehicles ....................................................................................... 10-6
§ 10:3.1 Introduction ............................................................... 10-6
§ 10:3.2 Manufacturing Defects .............................................. 10-8
§ 10:3.3 Design Defects ......................................................... 10-9
§ 10:3.4 Failure to Warn ........................................................ 10-11
§ 10:3.5 Use of Experts in Litigation ......................................... 10-12
§ 10:3.6 Moral Choices in Software Development ..................... 10-12
§ 10:4 Cybersecurity Concerns with Autonomous Vehicles ........................................................................................................... 10-13
§ 10:4.1 Data Mining and Autonomous Vehicles ...................... 10-13
§ 10:4.2 Propriety of Autonomous Vehicle Data ............ 10-14
§ 10:4.3 Terror Threats and Autonomous Vehicles .......... 10-14
§ 10:5 Implications for Ridesharing and Liability Under an Alternate Framework ........................................ 10-15

Chapter 11 Emerging Issues in Food Law and Litigation
Sarah L. Brew & Joelle Groshek

§ 11:1 Overview ........................................................................................................ 11-2
§ 11:2 Regulatory Framework ...................................................................................... 11-3
  § 11:2.1 Generally ..................................................................................................... 11-3
  § 11:2.2 FDA ............................................................................................................ 11-5
  § 11:2.3 USDA .......................................................................................................... 11-9
  § 11:2.4 FTC ............................................................................................................. 11-10
§ 11:3 Foodborne Illness Litigation ............................................................................. 11-11
  § 11:3.1 Generally ..................................................................................................... 11-11
  § 11:3.2 Strict Liability .............................................................................................. 11-12
  § 11:3.3 Defect .......................................................................................................... 11-13
    [A] Generally ......................................................................................................... 11-13
    [B] Definition of Defective Food ........................................................................... 11-13
    [C] Proof of Defect .................................................................................................. 11-16
  § 11:3.4 Causation ..................................................................................................... 11-17
  § 11:3.5 Causation in Foodborne Illness Outbreaks ............................................. 11-19
  § 11:3.6 Liability Across the Supply Chain ............................................................. 11-20
    [A] Generally ......................................................................................................... 11-20
    [B] Sellers and Distributors .................................................................................... 11-21
    [C] “Manufacturer” of Food Products ................................................................... 11-21
    [D] Third-Party Auditors/Consultants .................................................................. 11-22
§ 11:4 Class Actions .................................................................................................. 11-23
  § 11:4.1 Foodborne Illness Outbreaks ................................................................. 11-23
  § 11:4.2 Consumer Fraud Litigation .......................................................................... 11-25
    [A] Generally ......................................................................................................... 11-25
    [B] Reliance ............................................................................................................ 11-29
    [C] Causation ......................................................................................................... 11-30
    [D] Injury ................................................................................................................ 11-31
    [E] Failure to Sufficiently Plead ......................................................................... 11-31
    [F] Preemption and Primary Jurisdiction ............................................................ 11-31
§ 11:5 Conclusion ....................................................................................................... 11-37
## Chapter 12  Regulating Cannabis Products

*James H. Rotondo, Steven A. Cash & Kaitlin A. Canty*

<table>
<thead>
<tr>
<th>§</th>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>§ 12:1</td>
<td>Overview</td>
<td>12-1</td>
</tr>
<tr>
<td>§ 12:2</td>
<td>State and Federal Regulations</td>
<td>12-2</td>
</tr>
<tr>
<td>§ 12:2.1</td>
<td>Controlled Substances Act</td>
<td>12-2</td>
</tr>
<tr>
<td>[A]</td>
<td>Current Landscape</td>
<td>12-5</td>
</tr>
<tr>
<td>§ 12:2.2</td>
<td>2018 Farm Bill</td>
<td>12-6</td>
</tr>
<tr>
<td>§ 12:2.3</td>
<td>Food and Drug Administration</td>
<td>12-7</td>
</tr>
<tr>
<td>[A]</td>
<td>Approvals</td>
<td>12-7</td>
</tr>
<tr>
<td>[B]</td>
<td>FDA Support for Development</td>
<td>12-8</td>
</tr>
<tr>
<td>[C]</td>
<td>Enforcement and Possible Regulation</td>
<td>12-8</td>
</tr>
<tr>
<td>§ 12:2.4</td>
<td>State Legislation and Regulation</td>
<td>12-10</td>
</tr>
<tr>
<td>§ 12:2.5</td>
<td>Dual Sovereignty</td>
<td>12-14</td>
</tr>
<tr>
<td>§ 12:2.6</td>
<td>Preemption</td>
<td>12-15</td>
</tr>
<tr>
<td>§ 12:2.7</td>
<td>Current Case Law</td>
<td>12-16</td>
</tr>
<tr>
<td>[A]</td>
<td>Traditional Product Liability Claims</td>
<td>12-16</td>
</tr>
<tr>
<td>[B]</td>
<td>Labelling Class Actions</td>
<td>12-18</td>
</tr>
<tr>
<td>§ 12:3</td>
<td>Conclusion</td>
<td>12-19</td>
</tr>
</tbody>
</table>

## Chapter 13  Blockchain Technology and Its Impact on Product Litigation

*Justin Wales & Matt Kohen*

<table>
<thead>
<tr>
<th>§</th>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>§ 13:1</td>
<td>Introduction: Innovation Is Unpredictable</td>
<td>13-1</td>
</tr>
<tr>
<td>§ 13:2</td>
<td>Bitcoin, Blockchain, and Smart Contracts</td>
<td>13-3</td>
</tr>
<tr>
<td>§ 13:2.2</td>
<td>What Can a Blockchain Do?</td>
<td>13-4</td>
</tr>
<tr>
<td>§ 13:2.3</td>
<td>What Are Smart Contracts?</td>
<td>13-5</td>
</tr>
<tr>
<td>§ 13:3</td>
<td>Potential Impact on Existing Types of Products</td>
<td>13-6</td>
</tr>
<tr>
<td>§ 13:3.1</td>
<td>Use of Blockchain in Supply Chain Records</td>
<td>13-6</td>
</tr>
<tr>
<td>§ 13:3.2</td>
<td>Admissibility and Authentication of Blockchain Evidence</td>
<td>13-9</td>
</tr>
<tr>
<td>§ 13:3.3</td>
<td>Challenges in Discovering Blockchain Data</td>
<td>13-12</td>
</tr>
<tr>
<td>§ 13:4.1</td>
<td>Decentralized Autonomous Organizations (DAOs)</td>
<td>13-13</td>
</tr>
<tr>
<td>§ 13:4.2</td>
<td>Smart Contract Developer Liability</td>
<td>13-14</td>
</tr>
<tr>
<td>§ 13:5</td>
<td>Conclusion</td>
<td>13-15</td>
</tr>
</tbody>
</table>
# Chapter 14  Emerging Trends: Smart Technology and the Internet of Things

*Christopher C. Hossellman & Damion M. Young*

| § 14:1 | Overview | 14-2 |
| § 14:2 | Defining the Internet of Things | 14-3 |
| § 14:2.1 | Generally | 14-3 |
| § 14:2.2 | Examples of IoT Products | 14-4 |
| § 14:3 | Technology and Products Liability | 14-5 |
| § 14:3.1 | Products Liability and Technology Generally | 14-5 |
| § 14:3.2 | Examples of Early Technology Litigation | 14-6 |
| § 14:4 | What Makes IoT Different? | 14-8 |
| § 14:4.1 | The Scale of IoT | 14-8 |
| § 14:4.2 | Web Interconnectedness and Communication | 14-9 |
| § 14:4.3 | Botnets and IoT | 14-9 |
| § 14:5 | Considerations in IoT Products Liability Cases | 14-11 |
| § 14:5.1 | The Hypothetical Case of the Smart Toaster | 14-11 |
| § 14:5.2 | Pointing to the Defect | 14-12 |
| [A] | Malfunctions | 14-13 |
| [C] | Privacy | 14-14 |
| [D] | Artificial Intelligence and Autonomous Vehicles | 14-15 |
| § 14:5.3 | IoT Discovery: Challenges of Identifying Defects in IoT Cases and the Role of Experts | 14-17 |
| § 14:5.4 | IoT and the Consumer Expectation Test | 14-18 |
| § 14:5.5 | Assigning Blame | 14-20 |
| § 14:5.6 | Challenges in Holding Software Developers Liable for Defective IoT Products | 14-20 |
| § 14:5.7 | Standing Required | 14-21 |
| § 14:6 | Novel Legal Theories in an IoT Ecosystem | 14-21 |
| § 14:6.1 | Curtailing the Economic Loss Doctrine | 14-21 |
| § 14:6.2 | California’s SB-327 | 14-23 |
| § 14:6.3 | Federal Regulation of IoT | 14-25 |
| § 14:7 | Conclusion | 14-26 |

# Chapter 15  The Law of Damages in Product Liability Litigation

*Evan D. Buxner & Dionne L. Koller*

| § 15:1 | Generally | 15-2 |
| § 15:1.1 | Compensatory Damages | 15-2 |
| § 15:1.2 | Recovery for Emotional Distress | 15-3 |
| § 15:1.3 | Collateral Source Rule | 15-3 |
PART II
STRATEGIES FOR MANAGING AND RESOLVING
PRODUCT LITIGATION

Chapter 16  Using Early Case Assessments to
Develop Strategy

Mark E. (Rick) Richardson

§ 16:1  Overview ................................................................. 16-2
§ 16:2  Definition of Early Case Assessment ...................... 16-2
§ 16:3  Uses of Early Case Assessment .............................. 16-3
§ 16:4  Parsing the Definition ........................................... 16-4
    § 16:4.1  An Intentional Process ................................. 16-4
    § 16:4.2  With Specific Components ............................. 16-4
    § 16:4.3  Designed to Guide Strategy ............................ 16-5
    § 16:4.4  Done As Early As Possible ............................. 16-6
    § 16:4.5  Using Information That Will Be Incomplete
               but Not Inadequate ........................................... 16-7
              [A]  Focusing on Case-Determinative Information ...... 16-7
              [B]  Assessing the Importance of Unknown
                   Information: Sensitivity Analysis ................... 16-8
§ 16:5  Conducting the Early Case Assessment .................. 16-9
§ 16:6  Documenting the Early Case Assessment ................. 16-11
§ 16:7  Implementing the Early Case Assessment ................ 16-12
§ 16:8  Revisiting the Strategy ....................................... 16-13
## Table of Contents

§ 16:9 Building Strong Counsel/Client Ties ............................................. 16-14
§ 16:10 Conclusion .................................................................................. 16-14
Appendix 16A Template for an Early Case Assessment .......................... App. 16A-1

### Chapter 17 Impact of Insurance Policies

*Kamil Ismail, Linda S. Woolf & Richard M. Barnes*

§ 17:1 Coverage for Defense, Indemnification and/or Settlement of Products Liability Claims ............................................. 17-2
  § 17:1.1 Generally .................................................................................. 17-2
  § 17:1.2 Duty to Defend ....................................................................... 17-3
    [A] Generally .................................................................................... 17-3
    [B] Primary Policies ........................................................................... 17-3
    [C] Excess and Umbrella Policies ..................................................... 17-6
§ 17:2 Duty to Indemnify ....................................................................... 17-7
  § 17:2.1 Generally .................................................................................. 17-7
  § 17:2.2 Insuring Provisions ................................................................. 17-7
    [A] CGL Policies ................................................................................ 17-7
    [B] Claims-Made Policies ................................................................ 17-8
    [C] Excess and Umbrella Policies ..................................................... 17-9
    [D] Insured Contracts ....................................................................... 17-9
  § 17:2.3 Exclusions .............................................................................. 17-10
    [A] Generally ..................................................................................... 17-10
    [B] Products/Operations/Completed Operations ............................ 17-11
    [C] Known Losses ............................................................................ 17-12
    [D] Business Risks, Recalls ............................................................. 17-13
    [E] Punitive Damages ..................................................................... 17-14
  § 17:2.4 Conditions ............................................................................. 17-14
§ 17:3 Amount of Coverage Available .................................................. 17-16
  § 17:3.1 Policy Limits .......................................................................... 17-16
    [A] Aggregate, Per-Occurrence and “Batch” Limits ...................... 17-16
    [B] Number of Occurrences ............................................................ 17-16
    [C] Coverage Triggers for Long-Tail Personal Injury Claims .......... 17-19
    [D] “Stacking” of Policy Limits ......................................................... 17-21
    [E] Obligations of Multiple Insurers of the Same Insured in Long-Tail Personal Injury Claims ................................. 17-22
    [F] Exhaustion ................................................................................... 17-23
    [G] Operations vs. Products Limits .................................................... 17-24
  § 17:3.2 Supplementary Payments ....................................................... 17-25
§ 17:4 Emerging Issues ........................................................................... 17-25
  § 17:4.1 Autonomous Vehicles ............................................................. 17-25
  § 17:4.2 Drones .................................................................................... 17-26
  § 17:4.3 Cyber Risks ............................................................................ 17-26
Chapter 18  Advantages and Disadvantages of Multidistrict Litigation

Wendy R. Fleishman

§ 18:1  Overview ............................................................ 18-2
§ 18:2  Advantages of Multidistrict Litigation ................. 18-2
  § 18:2.1 Efficient and Expeditious Pretrial Procedures:
         Avoidance of Duplication .................................. 18-2
  § 18:2.2 Determinations by a Single Forum ................. 18-3
  § 18:2.3 A Global Point of View ................................ 18-5
§ 18:3  Disadvantages of the MDL Process .................. 18-6
§ 18:4  Defendant’s Perspective .................................... 18-6
  § 18:4.1 Benefits ...................................................... 18-6
    [A] Centralized Discovery ..................................... 18-7
    [B] Lower Transactional Costs ............................... 18-7
    [C] Single Dispositive Motions ............................. 18-8
    [D] Uniform Pleadings, Interrogatories, and Discovery Approaches ................. 18-8
    [E] Daubert Challenges ........................................ 18-8
  § 18:4.2 Disadvantages ............................................ 18-9
§ 18:5  Plaintiff’s Perspective ...................................... 18-10
  § 18:5.1 Benefits ...................................................... 18-10
  § 18:5.2 Disadvantages ............................................ 18-12
    [A] Inconvenient Forum ....................................... 18-12
    [B] Trial Delay ................................................... 18-12
    [C] Concern That Plaintiff’s Individual Interests May Be Lost or Forgotten .... 18-12
    [D] Challenges to Litigants by an Unfavorable View of the Law in One Circuit Versus Another Circuit ........................................... 18-13
    [E] Challenges to Plaintiffs’ Counsel and the Court: The Common Benefit Assessment Order and Sharing of Attorneys’ Fees ......... 18-14
§ 18:6  Conclusion ......................................................... 18-18
Chapter 19  Strategies for Co-Defending Product Actions

Lem E. Montgomery III & Anna Little Morris

§ 19:1  Overview ........................................................... 19-2
§ 19:2  Early Considerations in Multi-Defendant Actions .... 19-3
  § 19:2.1 Reconfiguring the Players................................. 19-3
  [A]  Generally ............................................................ 19-3
  [B]  Compulsory Joinder .............................................. 19-4
  [C]  Permissive Joinder and Severance ............................ 19-5
  [D]  Third-Party Practice ............................................ 19-6
§ 19:2.2 Coordinating Removal Among Co-Defendants .... 19-8
§ 19:3  Choosing the Defense Strategy ............................. 19-11
§ 19:4 Facilitating Cooperation Among Co-Defendants ...... 19-12
  § 19:4.1 The Joint Defense Privilege and Joint Defense
           Agreements .................................................... 19-12
  [A]  Generally ............................................................ 19-12
  [B]  Ethical Considerations Surrounding Joint
           Defense Agreements ........................................... 19-14
  [C]  Drafting the Joint Defense Agreement ...................... 19-19
§ 19:4.2 Informal Discovery Among Co-Defendants .......... 19-20
§ 19:5  Common Dangers of Joint Defense ........................ 19-21
  § 19:5.1 Protecting Confidential and Proprietary
           Information with Self-Executing and
           Multi-Tiered Protective Orders ............................... 19-21
§ 19:5.2 Ethical Considerations When Representing
           Multiple Defendants ........................................... 19-23
§ 19:5.3 Settlement Agreements Involving Less Than
           All Co-Defendants; the Dangers and Risks of
           Mary Carter Agreements ...................................... 19-26
§ 19:6  Cooperation Among Co-Defendants with Adverse
           Interests .......................................................... 19-29
  § 19:6.1 Dealing with Indemnity Obligations .................. 19-29
  § 19:6.2 Sharing (or Not Sharing) Experts ....................... 19-30
  § 19:6.3 Mediation Strategy and Settlement Allocation
           Among Co-Defendants ........................................ 19-32
  [A]  Generally ............................................................ 19-32
  [B]  Inform the Decision Makers ................................. 19-32
  [C]  Evaluate the Insurance Coverage ........................... 19-32
  [D]  Consider a Joint Mediation Plan ........................... 19-33
§ 19:6.4 Handling the Hostile Co-Defendant ....................... 19-33
§ 19:7  Checklist for Co-Defending Product Actions ........... 19-34

Chapter 20  Crisis Management and Media Strategy
   Joanne M. Gray & Nilda M. Isidro

§ 20:1  Overview ......................................................... 20-2
§ 20:2  The Media During a Crisis .................................... 20-3
   § 20:2.1  Role of the Media ......................................... 20-3
   § 20:2.2  Using the Media .......................................... 20-3
§ 20:2.3  Case Studies .................................................. 20-4
   [A]  Bridgestone/Firestone: What Not to Do When Faced with a Crisis ........................................... 20-4
       [A][1]  Background .................................................. 20-4
       [A][2]  Avoiding Responsibility ................................... 20-4
       [A][4]  Failure to Develop a Media Response Plan ....... 20-6
       [B][1]  Generally .................................................... 20-8
       [B][2]  Designating a Media Response Team ............... 20-8
   [C]  Chipotle: Course Correcting After Years of Poor Crisis Management ........................................... 20-10
   [D]  Cutting Out the “Pink Slime”: How McDonald’s Used Media Outreach to Diffuse the “Yuck” Factor ........................................... 20-12
§ 20:3  Developing an Effective Media Response Plan
   Before a Crisis Hits .................................................. 20-14
   § 20:3.1  Generally .................................................... 20-14
   § 20:3.2  Internal Organization—Forming a Media Response Team .................................................. 20-15
   § 20:3.3  Developing Media Relationships ..................... 20-15
   § 20:3.4  Establishing Online Support Systems ............. 20-16
   § 20:3.5  Conveying Company Commitment to Customers .................................................. 20-17
§ 20:4  Responding to a Crisis ......................................... 20-17
   § 20:4.1  Managing Media Under Fire ............................ 20-17
   § 20:4.2  Steps to Take When Responding to a Crisis ....... 20-17
       [A]  Developing a Strategic Media Message ............... 20-17
       [B]  Timely Delivery of Media Message .................... 20-18
       [C]  Opening Line of Communication ....................... 20-18
       [D]  Progressive Planning ....................................... 20-19
§ 20:5  Litigation and the Media ....................................... 20-19
   § 20:5.1  Litigation Avoidance ...................................... 20-19
   § 20:5.2  General Approach to Litigation ....................... 20-19
   § 20:5.3  Handling the Media Without Jeopardizing Lawsuits .................................................. 20-21
       [A]  Consistent Company Media Message and Strategy .................................................. 20-21
Table of Contents

[B] Retaining Experienced Legal Counsel.................. 20-21
[C] Consistent Company Media Message and
Strategy............................................................. 20-22
§ 20:6 Conclusion......................................................... 20-22

VOLUME 2

Table of Chapters........................................................................................................v

Chapter 21  Class Action Settlements
Richard B. Goetz, Carlos M. Lazatin &
Esteban Rodríguez

§ 21:1 Overview ................................................................ 21-3
§ 21:2 Features of Class Action Settlements.................... 21-4
  § 21:2.1 Role of the Class Representative and Class
  Counsel ..................................................................... 21-4
  [A] Traditional Settlements.................................. 21-4
  [B] Class Action Settlements.............................. 21-4
  § 21:2.2 Judicial Approval ........................................ 21-5
  [A] Need for Judicial Approval ......................... 21-5
  [B] Increased Judicial Scrutiny ...................... 21-6
  [C] Standard for Judicial Approval .............. 21-6
  § 21:2.3 Transparency in the Settlement Process ........ 21-8
  § 21:2.4 Multiple Parties with Goals of Derailment .... 21-9
    [A] Generally ................................................. 21-9
    [B] Differences in Goals and Acceptability of Terms ... 21-9
    [C] Class Member Objections ................. 21-10
  § 21:3 Basic Steps for Class Action Settlements ........ 21-11
    § 21:3.1 Generally ........................................... 21-11
    § 21:3.2 Negotiation Process ......................... 21-12
      [A] Generally ............................................. 21-12
      [B] Timing of the Class Settlement ......... 21-12
        [B][1] Generally ........................................... 21-12
        [B][2] Pre-Suit Settlements .................. 21-12
          [B][2][a] Advantages ....................... 21-12
          [B][2][b] Disadvantages .......... 21-13
        [B][3] Early Rulings ....................... 21-13
        [B][4] Class Certification Ruling ....... 21-14
        [B][5] Deciding Whether to Proceed to Trial .... 21-14
      [B][5][a] Generally .................................... 21-14

[B][5][b] Risks for Plaintiffs ........................................ 21-15
[B][5][c] Risks for Defendants ........................................ 21-15
[C] Good-Faith, Arm’s-Length Negotiations .................. 21-15
[D] Defining the Settlement Class ................................ 21-16
[D][1] For Plaintiffs .................................................... 21-16
[D][2] For Defendants .................................................. 21-17
[D][3] Sub-Classes ......................................................... 21-18
[D][4] Class Exclusions .................................................. 21-18
[E] Defining the Scope of the Release ......................... 21-19
[E][3] Who Will Be the “Released Parties”? ................. 21-21
[F] Consideration to Class Members ......................... 21-22
[F][1] Generally .......................................................... 21-22
[F][2] Settlement Fund Allocation ................................. 21-22
[F][2][a] Claims-Made versus Lump Sum/Common Fund Settlements ........................................ 21-22
[F][2][b] Coupon Settlements .......................................... 21-24
[F][2][c] Voucher Settlements .......................................... 21-29
[F][3] Settlements for Sub-Classes ............................. 21-31
[F][4] Undistributed or Unclaimed Distribution ............. 21-32
[F][4][a] Generally .......................................................... 21-32
[F][4][b] Cy Pres Funds .................................................... 21-32
[F][5] Equitable Relief or Changes in Business Practices .................................................. 21-35
[F][6] Fairness of the Settlement Consideration ............ 21-36
[G] Incentive Award to Class Representative ............. 21-37
[H] Confirmatory Discovery ......................................... 21-38
[I] Notice and Administration Procedures ................. 21-38
[I][1] Generally .......................................................... 21-38
[I][2] Notice’s Content and Methods of Distribution .................................................. 21-39
[I][2][a] First-Class Mail ............................................... 21-41
[I][2][b] Bulk Mail ........................................................ 21-42
[I][2][c] Email ............................................................... 21-42
[I][2][d] Other Methods of Notice ................................ 21-43
[I][3] Notice’s “Reach” .................................................. 21-43
[I][4] Settlement Administration ..................................... 21-44
[J] Negotiating Class Counsel’s Fees .......................... 21-44
[K] Drafting the Settlement Agreement .................... 21-46

§ 21:3.3 Preliminary Approval Process ....................... 21-47
[A] Generally .......................................................... 21-47
[B] Motion for Preliminary Approval ......................... 21-47
[B][1] Generally .......................................................... 21-47
Table of Contents

[B][2] Topics Covered by the Motion................................. 21-48
[B][2][a] Summary of the History of the Litigation..... 21-48
[B][2][b] Background of Settlement Negotiation........ 21-48
[B][2][c] Summary Description of Settlement Terms ... 21-49
[B][2][d] Provide Sound Bases for Modified Class Definition ..................................... 21-49
[B][2][e] Description of Key Factual and Legal Issues ........................................... 21-49
[B][2][f] Demonstrate Qualification for Class Certification ........................................ 21-50
[C] Preliminary Approval Hearing ............................................. 21-53
[D] Dealing with Potential Objectors ........................................... 21-54
[D][1] Generally........................................................................ 21-54
[D][2] Types of Objectors............................................................. 21-54
[D][3] Defeating Objectors.............................................................. 21-55
[D][4] Discovery of Objectors......................................................... 21-56
[D][5] Settling with Objectors.......................................................... 21-57
[E] Requests to Enjoin Competing Class Actions ..... 21-58
§ 21:3.4 Fairness Hearing Process......................................... 21-59
[A] Generally........................................................................ 21-59
[B] Setting the Timetable for the Fairness Hearing..... 21-60
[C] CAFA's Notice Requirements for Government Officials ........................................ 21-61
[D] Submissions for the Fairness Hearing ................. 21-62
[E] Use of Experts and Other Witnesses for the Fairness Hearing ................................ 21-63
[F] Conduct of the Fairness Hearing ........................................ 21-64
§ 21:4 Risks of a Failed Class Settlement ....................... 21-65
§ 21:4.1 Changes to the Players and Dynamics ......... 21-66
§ 21:4.2 Defendant's Diminished Leverage ............... 21-66
§ 21:4.3 Bar to Challenging Class Certification .......... 21-67
§ 21:4.4 Financial Impact on the Defendant ............. 21-68
§ 21:5 State Intervention in Class Action Settlements .... 21-68

Chapter 22 Mass Tort Settlement Strategies

Richard B. Goetz & Carlos M. Lazatin

§ 22:1 Overview ............................................................... 22-2
§ 22:2 Settlement Strategies ................................................. 22-3
§ 22:2.1 Settlement Class Actions ........................................ 22-3
[A] Generally ................................................................ 22-3
[B] Heightened Scrutiny of Certification Requirements ................................................. 22-5
[C] Opt-Out Rights............................................................. 22-6
[D] Appellate Review Concerns........................................... 22-8
§ 22:2.2  Inventory Settlements ............................................... 22-8
[A]  Generally ................................................................. 22-8
[B]  Benefits ................................................................. 22-9
[C]  Drawbacks ............................................................. 22-9
§ 22:2.3  Settlement Funds ...................................................... 22-11
§ 22:2.4  Hybrid Approach .................................................. 22-13
§ 22:2.5  Aggregate Settlement Agreements with Plaintiffs’ Attorneys ........................................... 22-14
[A]  Generally ................................................................. 22-14
[B]  Propulsid® Litigation ..................................................... 22-16
[B][1]  Background ........................................................... 22-16
[B][2]  First Settlement Agreement ...................................... 22-16
[B][3]  Second Settlement Agreement .................................. 22-18
§ 22:3  Private Settlement Agreement: Vioxx Settlement ...... 22-19
§ 22:3.1  Background .......................................................... 22-19
§ 22:3.2  Pre-Settlement Proceedings .................................. 22-19
§ 22:3.3  Settlement Agreement ........................................... 22-21
§ 22:3.4  Subsequent Developments and Issues .................... 22-27
§ 22:4  Additional Mass Tort Settlement Structure ................. 22-30
§ 22:5  The Negotiation Class ............................................. 22-34
§ 22:6  Additional Issues for Consideration ......................... 22-36

Chapter 23  Arbitration
Beth L. Kaufman & Charles B. Updike

§ 23:1  Overview .................................................................. 23-1
§ 23:2  Agreement to Arbitrate .............................................. 23-2
§ 23:2.1  Generally ............................................................ 23-2
§ 23:2.2  Benefits ............................................................... 23-3
§ 23:2.3  Pitfalls ................................................................. 23-3
[A]  Broad Language ......................................................... 23-3
[B]  Multiple Outcomes ..................................................... 23-4
[C]  Finality .................................................................... 23-5
§ 23:3  Post-Claim Agreements to Arbitrate ......................... 23-5
§ 23:4  Individual Claims by End-Users ............................... 23-6
§ 23:4.1  Generally ............................................................ 23-6
§ 23:4.2  Arbitration Considerations ..................................... 23-6
§ 23:4.3  Voluntary Arbitration Rules .................................... 23-7
§ 23:5  Arbitration in “Mass Tort” Product Liability Claims .................................................. 23-8
§ 23:5.1  Background .......................................................... 23-8
§ 23:5.2  Benefits ............................................................... 23-9
§ 23:6  Conclusion ............................................................... 23-10
Chapter 24  Privilege in a Global Product Economy
Marina G. McGuire

§ 24:1  Overview ................................................................. 24-2
§ 24:2  Attorney-Client Privilege ........................................ 24-3
  § 24:2.1  Generally ......................................................... 24-3
  § 24:2.2  Who Is the Client? ............................................. 24-5
  § 24:2.3  Whose Law Applies? ......................................... 24-7
§ 24:3  Question of Voluntary Waiver ................................. 24-9
  § 24:3.1  Voluntary Waiver During Government Investigations ........................................ 24-9
    [A]  “Holder” Memo .................................................... 24-9
    [B]  “Thompson” Memo ............................................... 24-10
    [C]  “McCallum” and “McNulty” Memos .................... 24-10
    [D]  Senator Arlen Specter and Deputy Attorney General Mark R. Filip ........................................ 24-12
    [E]  “Yates” Memo .......................................................... 24-14
§ 24:3.2  Voluntary Waiver During SEC Investigations .......... 24-15
    [A]  The Seaboard Report ............................................. 24-15
    [B]  The SEC’s Enforcement Manual and Enforcement Initiative ............................................ 24-16
§ 24:3.3  Selective Waiver .................................................. 24-18
§ 24:4  Questions of Involuntary Waiver by In-House Counsel During EU Investigations .................. 24-19
  § 24:4.1  Generally ........................................................... 24-19
  § 24:4.2  The “Attorney” and Privilege in the EU ................ 24-20
§ 24:5  Attorney-Client Privilege Issues Today ..................... 24-24
  § 24:5.1  The Implications of Voluntary Waiver ................ 24-24
  § 24:5.2  The Implications of Involuntary Waiver Post–Akzo Nobel ........................................... 24-25
§ 24:6  Conclusion ................................................................. 24-26

Chapter 25  E-Discovery—Practical Considerations
Denise J. Talbert, John C. Vaglio, Jeremiah S. Wikler & Christy A. Pulis

§ 25:1  Overview ................................................................. 25-2
§ 25:2  Guiding Principles .................................................. 25-3
  § 25:2.1  Generally ........................................................... 25-3
  § 25:2.2  Be Transparent .................................................. 25-4
  § 25:2.3  Be Technologically Competent ............................ 25-7
  § 25:2.4  Use Discovery Responses to Define Production Scope .................................................. 25-7
  § 25:2.5  Avoid Discovery on Discovery ............................ 25-8
§ 25:2.6 Comply with the Amended Federal Rules of Civil Procedure .................................................... 25-9
§ 25:2.7 Allow for Litigation-Specific Circumstances ...... 25-11
§ 25:3 Developing and Implementing the E-Discovery Plan .......................................................... 25-13

| § 25:3.1 Preservation .................................................. 25-13 |
| [B] Hold Notice Language and Distribution .................. 25-14 |
| [C] Continuing Obligation ........................................... 25-16 |
| [D] ESI Preservation Considerations .............................. 25-16 |
| [E] Separating Employees ........................................... 25-17 |
| [F] Tips to Reduce Preservation Costs .......................... 25-18 |

§ 25:3.2 Collection ........................................................... 25-18
| [A] Generally .......................................................... 25-18 |
| [B] Collection Plan .................................................. 25-19 |
| [B][1] Scope Statement ................................................ 25-19 |
| [B][2] Whom to Collect From ....................................... 25-20 |
| [B][3] Collection Interview ......................................... 25-20 |
| [C] Execution of a Document Collection ........................ 25-22 |
| [C][1] Hard Copy Collection ......................................... 25-22 |
| [C][2] Electronic Collection ......................................... 25-23 |
| [D] Tips to Reduce Collection Costs ............................... 25-25 |

§ 25:3.3 Processing ........................................................... 25-26
| [A] Vendors .............................................................. 25-26 |
| [B] Vendor Selection .................................................. 25-27 |
| [C] Processing Issues ................................................... 25-28 |
| [C][1] De-duplication .................................................. 25-28 |
| [C][2] Email Threading ................................................ 25-29 |
| [C][3] Filters ............................................................. 25-30 |
| [C][4] Review Enhancers .............................................. 25-30 |
| [D] Tips to Reduce Processing Costs ............................... 25-31 |

§ 25:3.4 Review .............................................................. 25-31
| [A] Review Guidelines ................................................ 25-31 |
| [A][1] Responsiveness .................................................. 25-32 |
| [A][2] Confidentiality ................................................... 25-32 |
| [A][3] Privilege .......................................................... 25-32 |
| [B] Review Team ........................................................ 25-33 |
| [C] Technology-Assisted Review ................................... 25-34 |

§ 25:3.5 Production .......................................................... 25-36
| [A] Protective Orders .................................................. 25-36 |
| [B] ESI Protocols ........................................................ 25-37 |
Chapter 26  Expert Evidence—Law, Strategies and Best Practices

Stephanie A. Scharf, George D. Sax, Sarah R. Marmor & Morgan G. Churma

§ 26:1  Overview ................................................................. 26-2
§ 26:2  Standards for Admissibility of Expert Opinions
   in Federal Court: Frye, Daubert, and Rule 702 .......... 26-4
  § 26:2.1  The Frye Standard ............................................. 26-4
  § 26:2.2  The Road to Daubert ....................................... 26-5
  § 26:2.3  Daubert and Its Aftermath .............................. 26-7
  § 26:2.4  Federal Rule of Evidence 702 .......................... 26-8
  § 26:2.5  Trial Court As Evidentiary Gatekeeper ............... 26-10
  § 26:2.6  Other Evidentiary Rules ................................. 26-11
§ 26:3  Current Issues Around Rule 702 ......................... 26-12
  § 26:3.1  Is It Time to Amend Rule 702? ......................... 26-12
  § 26:3.2  Application of Rule 702 ................................. 26-15
  § 26:3.3  Ongoing Differences Between Daubert and Frye ...... 26-17
§ 26:4  Exemplar States ..................................................... 26-19
  § 26:4.1  California ....................................................... 26-19
  § 26:4.2  Florida ........................................................... 26-21
  § 26:4.3  Illinois ......................................................... 26-23
  § 26:4.4  New Jersey ..................................................... 26-25
  § 26:4.5  New York ...................................................... 26-27
  § 26:4.6  Ohio ............................................................. 26-28
  § 26:4.7  Pennsylvania .................................................. 26-29
  § 26:4.8  Texas ............................................................ 26-31
§ 26:5  Daubert/Frye in Practice ...................................... 26-32
  § 26:5.1  Establishing Causation Through Expert
           Testimony ......................................................... 26-32
  § 26:5.2  Preparing for Daubert/Frye Challenges ............... 26-34
§ 26:6  Federal Rule of Civil Procedure 26 ....................... 26-38
§ 26:7  Conclusion .......................................................... 26-39
Appendix 26A  State Standards for Admissibility of

Chapter 27  Court-Appointed and Unconventional Expert Issues

Jonathan M. Hoffman

§ 27:1  Overview ................................................................. 27-2
§ 27:1.1 Reasons for Court-Appointed Experts ................. 27-3
§ 27:2  Court-Appointed Experts Under Rule 706 ................. 27-6
§ 27:2.1 Generally ............................................................... 27-6
§ 27:2.2 Interpretation of Rule 706’s Provisions ................. 27-7
  [A] Trial Court’s Discretion Whether to Appoint Experts ............................................................. 27-7
  [B] Procedure for Invoking Rule 706 ......................... 27-9
§ 27:2.3 Strategy ................................................................. 27-10
  [A] Whether the Court Should Appoint Its Own Experts ............................................................. 27-10
  [A][1] Benefits of Court-Appointed Experts ................. 27-10
  [C] Scope of Testimony ................................................ 27-15
§ 27:2.4 Instructions to Appointed Witnesses ................. 27-15
  [A] Text of Rule 706 ..................................................... 27-15
  [B] Strategy ................................................................. 27-15
    [B][1] Court’s Instructions to Appointed Witnesses ............................................................. 27-16
    [B][2] Research Methods of Court-Appointed Experts ............................................................. 27-16
    [B][3] Communications with Others .......................... 27-16
    [B][4] Ex Parte Communications with Parties or Their Experts ................................................ 27-17
    [B][5] Ex Parte Communications with the Court ...... 27-17
    [B][6] Acquisition of Information ............................. 27-18
    [B][7] Reports ............................................................. 27-18
    [B][9] Depositions ..................................................... 27-20
    [B][10] Motions in Limine ......................................... 27-20
  [C] Payment of Experts’ Costs ..................................... 27-21
§ 27:3  Technical Advisors .................................................. 27-21
§ 27:3.1 Generally ............................................................. 27-21
§ 27:3.2 Court’s Inherent Authority ................................. 27-22
§ 27:3.3 Procedural Protections ....................................... 27-24
§ 27:3.4 Costs ................................................................. 27-26
§ 27:4  Our Future? Getting Into the Hot Tub .................. 27-27
§ 27:4.1 Origins of Hot Tubbing ...................................... 27-27
§ 27:4.2 Hot Tubbing in the United States ...................... 27-28
# Chapter 28  Statistical Evidence in Products Liability Litigation

_Nathan A. Schachtman_

| § 28:1  | History and Overview | 28-2 |
| § 28:2  | Litigation Context of Statistical Issues | 28-3 |
| § 28:3  | Qualifications of Expert Witnesses Who Give Testimony on Statistical Issues | 28-4 |
| § 28:4  | Admissibility of Statistical Evidence—Rules 702 and 703 | 28-5 |
| § 28:5  | Significance Probability | 28-6 |
| § 28:5.1 | Definition of Significance Probability \((\text{The \textit{"p-value"}})\) | 28-6 |
| § 28:5.2 | Misstatements about Statistical Significance | 28-7 |
| § 28:5.3 | Transposition Fallacy | 28-12 |
| § 28:5.4 | Confusion Between Significance Probability and Burden of Proof | 28-13 |
| § 28:5.5 | Hypothesis Testing | 28-15 |
| § 28:5.6 | Confidence Intervals | 28-15 |
| § 28:5.7 | Inappropriate Use of Statistics—Matrixxx Initiatives | 28-17 |
| [A]  | Sequelae of Matrixxx Initiatives | 28-20 |
| [B]  | Is Statistical Significance Necessary? | 28-23 |
| § 28:5.8 | American Statistical Association's Statement on P-Values | 28-26 |
| § 28:6  | Statistical Power | 28-29 |
| § 28:6.1 | Definition of Statistical Power | 28-29 |
| § 28:6.2 | Cases Involving Statistical Power | 28-31 |
| § 28:7  | Evidentiary Rule of Completeness | 28-35 |
| § 28:8  | Meta-Analysis | 28-36 |
| § 28:8.1 | Definition and History of Meta-Analysis | 28-36 |
| § 28:8.2 | Consensus Statements | 28-37 |
| § 28:8.3 | Use of Meta-Analysis in Litigation | 28-37 |
| § 28:8.4 | Competing Models for Meta-Analysis | 28-41 |
| § 28:8.5 | Recent Cases Involving Meta-Analyses | 28-42 |
| § 28:9  | Statistical Inference in Securities Fraud Cases Against Pharmaceutical Manufacturers | 28-47 |
| § 28:10 | Multiple Testing | 28-53 |
| § 28:11 | Ethical Considerations Raised by Statistical Expert Witness Testimony | 28-55 |
| § 28:12 | Conclusion | 28-55 |
PART III
PARTICULAR ISSUES AND TACTICS

Chapter 29  Post-Sale Responsibilities in the United States and Foreign Countries
Kenneth Ross & George W. Soule

§ 29:1 Overview ................................................................................................................. 29-2
§ 29:2 U.S. Common Law ................................................................................................. 29-3
 § 29:2.1 Generally ............................................................................................................... 29-3
 § 29:2.2 Third Restatement Law on Post-Sale Duty to Warn ........................................ 29-3
 [A] Section 10 .................................................................................................................. 29-3
 [B] Section 11 .................................................................................................................. 29-4
 [C] Section 13 .................................................................................................................. 29-4
 § 29:2.3 State Courts ....................................................................................................... 29-5
 [A] Third Restatement ....................................................................................................... 29-5
 [B] Subsequent Safety Improvements ............................................................................. 29-5
§ 29:3 U.S. Regulatory Law ............................................................................................... 29-7
 § 29:3.1 Generally ............................................................................................................... 29-7
 § 29:3.2 Consumer Product Safety Act ........................................................................... 29-7
§ 29:4 Foreign Regulatory Activity ..................................................................................... 29-8
 § 29:4.1 Generally ............................................................................................................... 29-8
 § 29:4.2 European Response .............................................................................................. 29-8
 § 29:4.3 Foreign Standards and Regulations .................................................................... 29-9
§ 29:5 Meeting a Manufacturer’s Post-Sale Duties .......................................................... 29-10
 § 29:5.1 Information-Gathering Network ....................................................................... 29-10
 § 29:5.2 Risk Assessment .................................................................................................. 29-11
 § 29:5.3 Determining the Necessity of Post-Sale Action ............................................... 29-12
§ 29:6 Defending a Product After a Recall ........................................................................ 29-13
 § 29:6.1 Generally ............................................................................................................... 29-13
 § 29:6.2 Manufacturer Strategies ....................................................................................... 29-13
 [A] Act Decisively and Expedi tiously in Conducting the Recall .................................... 29-13
 [B] Draft the Recall Message with Care .......................................................................... 29-13
 [C] Identify “Losers” and “Winners” ................................................................................ 29-14
 [D] Weigh Pros and Cons of Excluding Recall Evidence ............................................. 29-14
 [E] Police Claims Against Manufacturer ....................................................................... 29-15
 [F] Put the Risk of Injury into Perspective ...................................................................... 29-16
 [G] Tell the Due Care Story ............................................................................................... 29-16
### Table of Contents

- [H] Prove Accident Not Due to Recall Condition ........................................ 29-16
- [I] Prove Another Factor Caused the Accident ........................................... 29-17
- [J] Try the Comparative Fault Case Against Others ...................................... 29-17

§ 29:7 Conclusion ................................................................................. 29-17

### Chapter 30  Role of Corporate Executives

*Samuel Goldblatt & Benjamin R. Dwyer*

- § 30:1 Overview .................................................................................. 30-1
- § 30:2 Limitations on Depositions of High-Level Executives ......................... 30-2
  - § 30:2.1 Generally ............................................................................. 30-2
  - § 30:2.2 Law of “Apex” Depositions .................................................... 30-4
  - § 30:2.3 Unique or Superior Knowledge ................................................ 30-7
  - § 30:2.4 Less Burdensome Means ....................................................... 30-12
- § 30:3 Plaintiff’s Strategic Considerations .................................................. 30-18
- § 30:4 Defense’s Strategic Considerations ................................................... 30-20
- § 30:5 Negotiating the Scope of Depositions ................................................. 30-22
- § 30:6 Preparation of a High-Level Executive for Deposition and Trial ............... 30-22
- § 30:7 Conclusion .................................................................................. 30-23

### Chapter 31  Contacting Corporate Employees

*Sharon L. Caffrey, Kenneth M. Argentieri & Rachel M. Good*

- § 31:1 Overview .................................................................................. 31-1
- § 31:2 Initiating an Ex Parte Communication ............................................... 31-2
  - § 31:2.1 Initial Considerations ................................................................ 31-2
  - § 31:2.2 Applicable Rules .................................................................... 31-2
- § 31:3 Who Is a Represented Party? ............................................................ 31-5
  - § 31:3.1 Model Rule 4.2 ..................................................................... 31-5
  - § 31:3.2 Court Opinions ..................................................................... 31-6
  - § 31:3.3 American Bar Association ....................................................... 31-9
- § 31:4 Claiming an Attorney-Client Relationship ......................................... 31-10
  - § 31:4.1 Attorney-Client Privilege ....................................................... 31-10
  - § 31:4.2 Protecting Confidential Information ......................................... 31-11
- § 31:5 Conclusion .................................................................................. 31-13
Chapter 32  Spoliation of Product Evidence

Paul E. Benson & Adam E. Witkov

§ 32:1  Overview ........................................................................................................... 32-2
§ 32:2  History of Spoliation of Evidence ................................................................. 32-3
§ 32:3  Analysis of Recent Trends in Spoliation ...................................................... 32-4
  § 32:3.1  Generally ...................................................................................................... 32-4
  § 32:3.2  Reasonably Foreseeable Litigation and Document Retention Policies .... 32-4
  § 32:3.3  Spoliation of Electronically Stored Information .................................. 32-5
  § 32:3.4  State Court Trends .................................................................................. 32-6
§ 32:4  Negligent Spoliation ....................................................................................... 32-7
  § 32:4.1  Generally ...................................................................................................... 32-7
  § 32:4.2  Negligent Spoliation by a Plaintiff ......................................................... 32-8
  § 32:4.3  Negligent Spoliation by a Defendant ....................................................... 32-9
  § 32:4.4  Negligent Spoliation by a Third Party .................................................... 32-11
    [A]  Generally ......................................................................................................... 32-11
    [B]  Duty to Preserve Evidence ........................................................................... 32-12
§ 32:5  Intentional Spoliation ....................................................................................... 32-14
  § 32:5.1  Generally ...................................................................................................... 32-14
  § 32:5.2  Intentional Spoliation by a Plaintiff ......................................................... 32-14
  § 32:5.3  Intentional Spoliation by a Defendant ....................................................... 32-15
  § 32:5.4  Intentional Spoliation by a Third Party .................................................... 32-18
    [A]  Generally ......................................................................................................... 32-18
    [B]  Third-Party Intentional Spoliation Not Protected ........................................ 32-20
§ 32:6  Defenses and Sanctions .................................................................................... 32-21
  § 32:6.1  Defenses ....................................................................................................... 32-21
    [A]  Good Faith ....................................................................................................... 32-21
    [B]  Opportunity to Examine ............................................................................... 32-22
    [C]  Immaterial Evidence ...................................................................................... 32-23
    [D]  Statutes of Limitations .................................................................................. 32-23
  § 32:6.2  Sanctions ...................................................................................................... 32-24
    [A]  Generally ......................................................................................................... 32-24
    [B]  Dismissal .......................................................................................................... 32-25
    [C]  Monetary Sanctions ....................................................................................... 32-26
    [D]  Spoliation Inference/Rebuttable Presumption ............................................ 32-27
    [E]  Criminal Liability for Obstruction of Justice .............................................. 32-29
§ 32:7  Evolving Areas ................................................................................................ 32-30
  § 32:7.1  Party Sophistication .................................................................................. 32-30
  § 32:7.2  Video Evidence ......................................................................................... 32-30
  § 32:7.3  Freedom of Information Act (FOIA) ....................................................... 32-31
§ 32:8  Attorney Duties ............................................................................................... 32-31
§ 32:9  Conclusion ....................................................................................................... 32-32
### Chapter 33  Presenting Complex Scientific Evidence

*Morton D. Dubin II & Nina Trovato*

<table>
<thead>
<tr>
<th>§</th>
<th>Overview</th>
<th>33-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>§ 33:2</td>
<td>Selecting a Message</td>
<td>33-2</td>
</tr>
<tr>
<td>§ 33:2.1</td>
<td>Generally</td>
<td>33-2</td>
</tr>
<tr>
<td>§ 33:2.2</td>
<td>Understand the Scientific Evidence</td>
<td>33-3</td>
</tr>
<tr>
<td>§ 33:2.3</td>
<td>Simplify the Trial Message</td>
<td>33-3</td>
</tr>
<tr>
<td>§ 33:2.4</td>
<td>Expert Credibility Themes</td>
<td>33-4</td>
</tr>
<tr>
<td>§ 33:3</td>
<td>Selecting a Messenger—Importance of the Right Expert</td>
<td>33-6</td>
</tr>
<tr>
<td>§ 33:4</td>
<td>Considerations During Phases of the Trial Process</td>
<td>33-7</td>
</tr>
<tr>
<td>§ 33:4.1</td>
<td>Jury Selection</td>
<td>33-7</td>
</tr>
<tr>
<td>§ 33:4.2</td>
<td>Opening</td>
<td>33-7</td>
</tr>
<tr>
<td>§ 33:4.3</td>
<td>Direct Examination</td>
<td>33-8</td>
</tr>
<tr>
<td>[A]</td>
<td>State Opinions at the Outset</td>
<td>33-8</td>
</tr>
<tr>
<td>[B]</td>
<td>Tactical Presentation of Qualifications</td>
<td>33-9</td>
</tr>
<tr>
<td>[C]</td>
<td>Use of Visual Aids</td>
<td>33-10</td>
</tr>
<tr>
<td>[D]</td>
<td>Get Experts on Their Feet</td>
<td>33-10</td>
</tr>
<tr>
<td>[E]</td>
<td>Develop Themes</td>
<td>33-10</td>
</tr>
<tr>
<td>[F]</td>
<td>Draw Implied Conclusions</td>
<td>33-11</td>
</tr>
<tr>
<td>[G]</td>
<td>Understand Local Rules on Learned Treatises</td>
<td>33-11</td>
</tr>
<tr>
<td>[H]</td>
<td>“Gateway” Requirements</td>
<td>33-13</td>
</tr>
<tr>
<td>§ 33:4.4</td>
<td>Cross-Examination</td>
<td>33-14</td>
</tr>
<tr>
<td>[A]</td>
<td>Understand Local Rules on Learned Treatises</td>
<td>33-14</td>
</tr>
<tr>
<td>[B]</td>
<td>Know Your Limitations and the Skill of the Expert</td>
<td>33-16</td>
</tr>
<tr>
<td>[C]</td>
<td>Focus on the Understandable</td>
<td>33-16</td>
</tr>
<tr>
<td>[D]</td>
<td>Best Available Tools for Organization and Presentation</td>
<td>33-17</td>
</tr>
<tr>
<td>[E]</td>
<td>Strategic Use of Bias Information</td>
<td>33-17</td>
</tr>
<tr>
<td>§ 33:4.5</td>
<td>Closing</td>
<td>33-17</td>
</tr>
</tbody>
</table>

### Chapter 34  How to Win a Dismissal When the Plaintiff Declares Bankruptcy

*Anita Hotchkiss & Earyn Edwards*

| § 34:1 | Overview                                                                 | 34-2 |
| § 34:2 | Types of Bankruptcies                                                   | 34-3 |
| § 34:2.1 | Chapter 7                                                               | 34-4 |
| § 34:2.2 | Chapter 13                                                              | 34-4 |
| § 34:3 | Duty to Disclose Pending and Contingent Claims                          | 34-5 |
| § 34:3.1 | Generally                                                               | 34-5 |
| § 34:3.2 | Definition of “Pending Claims”                                           | 34-5 |
§ 34:4 Standing ............................................................... 34-6
§ 34:4.1 Generally ......................................................... 34-6
§ 34:4.2 Standing and Bankruptcy .................................... 34-6
§ 34:5 Judicial Estoppel .................................................. 34-8
§ 34:5.1 Generally ......................................................... 34-8
§ 34:5.2 Judicial Estoppel and Bankruptcy ....................... 34-9
§ 34:5.3 Elements Needed to Prove Entitlement to Summary Judgment ......................................................... 34-11
[A] Generally ............................................................... 34-11
[B] Knowledge ............................................................... 34-12
[C] Bad Faith ................................................................. 34-13
[D] Detrimental Reliance ............................................... 34-15
[E] Public Policy ............................................................. 34-15
§ 34:5.4 Choice of Law .................................................... 34-15
[A] Generally ............................................................... 34-15
[B] Property Exemptions Specific to Particular Jurisdictions ................................................................. 34-16
[C] Significance of the Amount of Debt Discharged .............................................................................. 34-17
§ 34:6 Securing Dismissal or Summary Judgment .......... 34-17
§ 34:7 Plaintiff’s Responses to an Estoppel Motion ......... 34-19
§ 34:7.1 Generally ........................................................... 34-19
§ 34:7.2 Amending the Bankruptcy Petition ..................... 34-20
§ 34:7.3 Allowing the Bankruptcy Trustee to Prosecute the Case ......................................................... 34-21
§ 34:7.4 Suing the Bankruptcy Attorney for Malpractice ........................................................................... 34-22
§ 34:8 Conclusion ............................................................ 34-22
Appendix 34A Cases Seeking Summary Judgment/Dismissal Based Upon Judicial Estoppel and/or Lack of Standing ......................................................... App. 34A-1

Chapter 35 Juries

Christopher C. Spencer

§ 35:1 Introduction ......................................................... 35-2
§ 35:2 Why Go to Trial? .................................................... 35-3
§ 35:3 The Modern Jury Trial ............................................ 35-4
§ 35:4 The Modern Jury .................................................... 35-4
§ 35:5 Preparing for Your Performance ......................... 35-7
§ 35:5.1 First Steps .......................................................... 35-8
§ 35:5.2 Take Control of the Narrative .............................. 35-9
§ 35:5.3 Experts ................................................................. 35-10
§ 35:5.4 Taking Depositions .............................................. 35-11
## Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>§ 35:5.5 Defending Depositions</td>
<td>35-12</td>
</tr>
<tr>
<td>§ 35:5.6 Jury Research</td>
<td>35-14</td>
</tr>
<tr>
<td>§ 35:6 Staging</td>
<td>35-14</td>
</tr>
<tr>
<td>§ 35:6.1 Jury Instructions and Verdict Form</td>
<td>35-15</td>
</tr>
<tr>
<td>§ 35:6.2 Pretrial Motions</td>
<td>35-16</td>
</tr>
<tr>
<td>§ 35:6.3 Exhibits</td>
<td>35-16</td>
</tr>
<tr>
<td>§ 35:6.4 Witnesses</td>
<td>35-19</td>
</tr>
<tr>
<td>§ 35:6.5 Get Acquainted with the Courtroom</td>
<td>35-20</td>
</tr>
<tr>
<td>§ 35:7 Showtime</td>
<td>35-21</td>
</tr>
<tr>
<td>§ 35:7.1 First Impressions</td>
<td>35-21</td>
</tr>
<tr>
<td>§ 35:7.2 Look Your Part</td>
<td>35-22</td>
</tr>
<tr>
<td>§ 35:7.3 Have Your Witnesses and Representatives Look Their Parts</td>
<td>35-22</td>
</tr>
<tr>
<td>§ 35:7.4 First Impressions, Continued</td>
<td>35-23</td>
</tr>
<tr>
<td>§ 35:7.5 Picking the Jury</td>
<td>35-24</td>
</tr>
<tr>
<td>§ 35:7.6 Opening</td>
<td>35-24</td>
</tr>
<tr>
<td>§ 35:7.7 The Evidence</td>
<td>35-25</td>
</tr>
<tr>
<td>§ 35:7.8 The Defense and Damages</td>
<td>35-25</td>
</tr>
<tr>
<td>§ 35:7.9 The Plaintiff and Anger</td>
<td>35-26</td>
</tr>
<tr>
<td>§ 35:7.10 Lead the Jury, Don't Push It</td>
<td>35-26</td>
</tr>
<tr>
<td>§ 35:7.11 Closing</td>
<td>35-26</td>
</tr>
<tr>
<td>§ 35:8 Conclusion</td>
<td>35-26</td>
</tr>
</tbody>
</table>

## Chapter 36 Preparing for the Appeal

*Wendy F. Lumish & Alina Alonso Rodriguez*

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>§ 36:1 Overview</td>
<td>36-2</td>
</tr>
<tr>
<td>§ 36:2 Pre-Trial</td>
<td>36-2</td>
</tr>
<tr>
<td>§ 36:2.1 Drafting Pleadings and Dispositive Motions</td>
<td>36-2</td>
</tr>
<tr>
<td>§ 36:2.2 Motions in Limine</td>
<td>36-3</td>
</tr>
<tr>
<td>§ 36:2.3 Experts</td>
<td>36-5</td>
</tr>
<tr>
<td>§ 36:2.4 Pre-Trial Stipulation</td>
<td>36-6</td>
</tr>
<tr>
<td>§ 36:3 Trial</td>
<td>36-7</td>
</tr>
<tr>
<td>§ 36:3.1 The Record</td>
<td>36-7</td>
</tr>
<tr>
<td>[A] Generally</td>
<td>36-7</td>
</tr>
<tr>
<td>[B] Depositions</td>
<td>36-8</td>
</tr>
<tr>
<td>[C] Exhibits</td>
<td>36-8</td>
</tr>
<tr>
<td>[D] Non-Verbal Conduct</td>
<td>36-9</td>
</tr>
<tr>
<td>[E] Filing Documents During Trial</td>
<td>36-10</td>
</tr>
<tr>
<td>§ 36:3.2 Voir Dire</td>
<td>36-10</td>
</tr>
<tr>
<td>§ 36:3.3 Evidentiary Objections</td>
<td>36-12</td>
</tr>
<tr>
<td>§ 36:3.4 Expert Testimony Revisited</td>
<td>36-15</td>
</tr>
<tr>
<td>§ 36:3.5 Proffers of Evidence</td>
<td>36-16</td>
</tr>
<tr>
<td>§ 36:3.6 Motion for Directed Verdict</td>
<td>36-16</td>
</tr>
<tr>
<td>§ 36:3.7 Jury Instructions</td>
<td>36-17</td>
</tr>
</tbody>
</table>
Chapter 37  Global Reach: Foreign Defendants in the United States

Lisa J. Savitt

§ 37:1  Introduction ................................................................. 37-2
§ 37:2  Initial Considerations .................................................. 37-3
   § 37:2.1  Service of Process .................................................. 37-3
   § 37:2.2  Internationally Agreed Means of Service ................. 37-4
   § 37:2.3  Waiver ................................................................. 37-5
   § 37:2.4  Service of Process Under the Foreign Sovereign Immunities Act (FSIA) ........................................ 37-5
   § 37:2.5  Removal ................................................................. 37-7
   § 37:2.6  Duty to Preserve and Litigation Hold ....................... 37-7
   § 37:2.7  Personal Jurisdiction .............................................. 37-7
      [A]  Specific Jurisdiction ................................................... 37-8
      [A][1]  Post Bristol-Myers Decisions ................................. 37-11
      [B]  General Jurisdiction .................................................. 37-12
      [B][1]  Legal Challenges to Daimler and Progeny ............ 37-13
      [C]  Practical Considerations ........................................... 37-13
   § 37:2.8  Subject Matter Jurisdiction ................................... 37-13
   § 37:2.9  The Foreign Sovereign Immunities Act (FSIA) ....... 37-14
   § 37:2.10  Forum Non Conveniens ....................................... 37-14
§ 37:3  Considerations During Litigation ................................ 37-15
   § 37:3.1  Discovery Issues .................................................. 37-15
   § 37:3.2  Hague Convention on Taking of Evidence Abroad .................. 37-16
   § 37:3.3  Foreign Privacy Issues ........................................... 37-17
   § 37:3.4  Attorney-Client Privilege ..................................... 37-17
   § 37:3.5  Application of Foreign Law ................................... 37-18
§ 37:4  Other Differences ...................................................... 37-19
§ 37:5  Enforcement of Judgments .......................................... 37-19
§ 37:6  Cultural Issues ......................................................... 37-20
§ 37:7  Conclusion ............................................................... 37-20

Table of Cases ........................................................................ T-1
Index ..................................................................................... I-1

lxvii